Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTIJP3Q)

• DTT Name: TNF related activation protein (CD40LG) DTT Info
• Gene Name: CD40LG

Molecule-Related Drug & Molecule List

12 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[1]
Dapirolizumab pegol	DMIYFWA	Systemic lupus erythematosus	4A40.0	Phase 2	[2]
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[3]
ISF35	DMBZK3P	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[4]
Lucatumumab	DMY2L7V	Lymphoma	2A80-2A86	Phase 2	[5]
PG-102	DMF5YEN	Autoimmune diabetes	5A10	Phase 2	[6]
ABBV-428	DMPD0KL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
BPX-101	DM51MSD	Prostate cancer	2C82.0	Phase 1	[8]
CDP-7657	DMN8I5Q	Systemic lupus erythematosus	4A40.0	Phase 1	[9]
Chi Lob 7/4	DMSOB5D	B-cell lymphoma	2A86	Phase 1	[10]
MEDI4920	DME7BMT	Rheumatoid arthritis	FA20	Phase 1	[11]
UltraCD40L	DMHG7DZ	Systemic lupus erythematosus	4A40.0	Phase 1	[12]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IDEC-131	DMAU79Q	Thrombocytopenia	3B64	Discontinued in Phase 1	[13]
Antova	DMXKZDU	Thrombocytopenia	3B64	Terminated	[14]
Dacetuzumab	DMP3X6Q	Diffuse large B-cell lymphoma	2A81	Terminated	[15]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TriMixDC	DML3OYH	Melanoma	2C30	Investigative	[16]

References

• [1] FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [4] Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25.
• [5] Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42.
• [6] Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.
• [9] CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234.
• [10] Agonistic CD40 antibodies and cancer therapy
• [11] ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health.
• [12] CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357.
• [13] Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan;28(1):95-101.
• [14] CD40 and Autoimmunity: The Dark Side of a Great Activator
• [15] A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.Leuk Lymphoma.2010 Feb;51(2):228-35.
• [16] Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.